170 related articles for article (PubMed ID: 36511902)
1. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
Ma C; Zhou Y; Fanelli GN; Stopsack KH; Fiorentino M; Zadra G; Mucci LA; Loda M; Tyekucheva S; Penney KL
Mol Cancer Res; 2023 Mar; 21(3):253-260. PubMed ID: 36511902
[TBL] [Abstract][Full Text] [Related]
2. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer.
Hesterberg AB; Rios BL; Wolf EM; Tubbs C; Wong HY; Schaffer KR; Lotan TL; Giannico GA; Gordetsky JB; Hurley PJ
J Pathol Clin Res; 2021 May; 7(3):271-286. PubMed ID: 33600062
[TBL] [Abstract][Full Text] [Related]
3. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
4. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.
Andersen MK; Rise K; Giskeødegård GF; Richardsen E; Bertilsson H; Størkersen Ø; Bathen TF; Rye M; Tessem MB
Sci Rep; 2018 Sep; 8(1):14269. PubMed ID: 30250137
[TBL] [Abstract][Full Text] [Related]
5. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.
Lu D; Sinnott JA; Valdimarsdóttir U; Fang F; Gerke T; Tyekucheva S; Fiorentino M; Lambe M; Sesso HD; Sweeney CJ; Wilson KM; Giovannucci EL; Loda M; Mucci LA; Fall K
Clin Cancer Res; 2016 Feb; 22(3):765-772. PubMed ID: 26490316
[TBL] [Abstract][Full Text] [Related]
6. Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Roberto D; Selvarajah S; Park PC; Berman D; Venkateswaran V
Prostate; 2019 Nov; 79(15):1777-1788. PubMed ID: 31503357
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
8. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
Magi-Galluzzi C; Maddala T; Falzarano SM; Cherbavaz DB; Zhang N; Knezevic D; Febbo PG; Lee M; Lawrence HJ; Klein EA
Oncotarget; 2016 Jun; 7(23):33855-65. PubMed ID: 27121323
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes.
Ashida S; Orloff MS; Bebek G; Zhang L; Zheng P; Peehl DM; Eng C
Clin Cancer Res; 2012 Mar; 18(6):1578-87. PubMed ID: 22275508
[TBL] [Abstract][Full Text] [Related]
10. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
11. Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
Mahal BA; Alshalalfa M; Zhao SG; Beltran H; Chen WS; Chipidza F; Davicioni E; Karnes RJ; Ku SY; Lotan TL; Muralidhar V; Rebbeck TR; Schaeffer EM; Spratt DE; Feng FY; Nguyen PL
Cancer; 2020 Apr; 126(7):1407-1412. PubMed ID: 31905251
[TBL] [Abstract][Full Text] [Related]
12. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.
Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA
J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668
[TBL] [Abstract][Full Text] [Related]
13. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
[TBL] [Abstract][Full Text] [Related]
15. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.
Kinseth MA; Jia Z; Rahmatpanah F; Sawyers A; Sutton M; Wang-Rodriguez J; Mercola D; McGuire KL
Int J Cancer; 2014 Jan; 134(1):81-91. PubMed ID: 23754304
[TBL] [Abstract][Full Text] [Related]
16. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.
Hägglöf C; Hammarsten P; Josefsson A; Stattin P; Paulsson J; Bergh A; Ostman A
PLoS One; 2010 May; 5(5):e10747. PubMed ID: 20505768
[TBL] [Abstract][Full Text] [Related]
17. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
18. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of periostin in stroma positively associated with aggressive prostate cancer.
Tian Y; Choi CH; Li QK; Rahmatpanah FB; Chen X; Kim SR; Veltri R; Chia D; Zhang Z; Mercola D; Zhang H
PLoS One; 2015; 10(3):e0121502. PubMed ID: 25781169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
